Impact of Long-term Systemic Corticosteroid Therapy on Immune Response to the Influenza Vaccine: A Review of the Literature—How about COVID-19 Vaccine

2021 ◽  
Author(s):  
Shuyao Pan ◽  
Gang Chen
Keyword(s):  
Immune Response ◽  
Influenza Vaccine ◽  
Corticosteroid Therapy ◽  
Systemic Corticosteroid ◽  
Review Of The Literature ◽  
Systemic Corticosteroid Therapy

scholarly journals A Long-Term Control of Intramedullary Thoracic Spinal Cord Metastasis from Small Cell Lung Cancer

2018 ◽  
Vol 61 (2) ◽  
pp. 57-59 ◽  
Author(s):  
Hajime Osawa ◽  
Shinichiro Okauchi ◽  
Gen Ohara ◽  
Katsunori Kagohashi ◽  
Hiroaki Satoh
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Corticosteroid Therapy ◽  
Cell Lung Cancer ◽  
Systemic Corticosteroid ◽  
Small Cell ◽  
Small Cell Lung ◽  
Systemic Corticosteroid Therapy

Radiotherapy with systemic corticosteroid therapy has been used to treat intramedullary spinal cord metastasis (ISCM), but recovery of function and long-term survival of these patients has been rarely observed. We report herein a small cell lung cancer (SCLC) patient with recurrent thoracic ISCM, who was successfully treated with radiotherapy and systemic corticosteroid therapy. A 70-year-old man, who was diagnosed as having SCLC seven months previously, developed thoracic ISCM. Soon after the detection of the lesion, the patient received radiotherapy with systemic corticosteroid therapy. Sensory disturbance in both extremities and neurogenic bladder and bowel dysfunction was recovered. The patient could walk after irradiation again. The patient received additional chemotherapy and survived 20 months after the diagnosis of ISCM recurrence. Prompt diagnosis and appropriate treatment for ISCM and effective chemotherapy for recurrent SCLC might be the favorable factors for such patients. Further studies will be required to define a favorable subset of patients most likely to benefit from a conventional approach.

IgE LEVELS IN SERA OF CHILDREN WITH ASTHMA

PEDIATRICS ◽  
1971 ◽  
Vol 47 (5) ◽  
pp. 848-856
Author(s):  
Lata Kumar ◽  
Richard W. Newcomb ◽  
Kimishige Ishizaka ◽  
Elliott Middleton ◽  
Margaret M. Hornbrook
Keyword(s):  
Atopic Dermatitis ◽  
Bronchial Asthma ◽  
Corticosteroid Therapy ◽  
Systemic Corticosteroid ◽  
Skin Tests ◽  
Positive Skin ◽  
Children With Asthma ◽  
Severity Of The Disease ◽  
Systemic Corticosteroid Therapy

Concentrations of the immunoglobulin that is associated with reaginic activity, IgE (γE), were measured in sera of 116 children with bronchial asthma. High γE (>700 ng/ml) were found in only 30. High γE levels were found in children with many positive skin tests (P < 0.01) and with active atopic dermatitis (P < 0.01). Long term, systemic corticosteroid therapy was found to be associated with normal γE values (P < .001) even when the characteristics of the disease would otherwise have indicated high values. As no correlation is found to be evident between severity of the disease and γE levels, it may be suggested that corticosteroids may decrease intravascular γE. The serum γE values failed to reveal two or more clinically different groups among our patients.

scholarly journals Assessment of glycemic status of COPD patients on long term corticosteroid therapy

2017 ◽  
Vol 5 (9) ◽  
pp. 3997
Author(s):  
Vivek Kumar Verma ◽  
Ranjit Kumar Nim ◽  
Manoj Kumar ◽  
Premshanker Singh ◽  
Geeta Singh ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Corticosteroid Therapy ◽  
Systemic Corticosteroid ◽  
Inhaled Corticosteroids ◽  
Beta Agonist ◽  
Airflow Limitation ◽  
Glycemic Status ◽  
Copd Patients ◽  
Systemic Corticosteroid Therapy

Background: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Among the pharmacological therapy, inhaled beta- agonist and anticholinergics are the mainstay therapy of COPD along with corticosteroid. Steroid therapy is associated with various potential adverse effects like steroid induced deranged glycemic status. So, we sought to examine the association between long term corticosteroid therapy and glycemic status in COPD patients.Methods: A cross sectional study was done to assess the glycemic status in COPD patients on long term corticosteroid therapy in a rural tertiary care centre on patients satisfying inclusion and exclusion criteria. Inclusion criteria includes COPD patients on steroid based therapy (inhaled/systemic or both) for at least 6 months. Known case of type 2 diabetes mellitus, bronchial asthma, interstitial lung disease, coronary artery disease, cardiomyopathies, connective tissue disorders, recipients of organ transplant or immunosuppressive therapy, patients having co morbidities like renal failure, liver failure, heart failure and patients on other drugs known to cause hyperglycemia were excluded. Random blood sugar, HbA1C etc, was done and data was analyzed by SPSS version 22.0.Results: Total 46 patients were included in study. Mean age was 63.22 years with minimum age 47 years and maximum age 80 years. 35 patients (76.09%) were male and 11 patients (23.91%) were female. Sex ratio was 3.18:1. 26 patients (56.52%) were taking both inhaled and systemic corticosteroids, 12 patients (26.09%) were taking only inhaled corticosteroids and 8 patients (17.39%) were taking systemic corticosteroid therapy. 14 patients (30.43%) were found to have impaired glucose tolerance, 7 patients (15.22%) were diagnosed as a case of diabetes mellitus and 25 patients (54.35%) were found to be euglycemic.Conclusions: We conclude that incidence of deranged glycemic status is more common among COPD patients receiving only systemic corticosteroid therapy or both systemic and inhaled corticosteroid therapy. Further, inhaled corticosteroids are better in terms of glycemic control among COPD patients on corticosteroid therapy. Hence, we recommend routine screening of glycemic status in COPD patients on corticosteroid therapy.

Topical corticosteroids in ulcerative colitis

1975 ◽  
Vol 13 (2) ◽  
pp. 5-7
Keyword(s):  
Ulcerative Colitis ◽  
Corticosteroid Therapy ◽  
Systemic Corticosteroid ◽  
Extensive Disease ◽  
Double Blind ◽  
Topical Corticosteroids ◽  
Systemic Corticosteroid Therapy ◽  
Blind Trials

Since the usefulness of topical corticosteroids in the treatment of ulcerative colitis was first reported1 double-blind trials have confirmed their effectiveness, and they are now widely used.2 For disease localised to the rectum suppositories, and for more extensive disease, retention enemas containing various corticosteroids are available (see table). In severe cases these preparations also valuably supplement systemic corticosteroid therapy, with or without sulphasalazine (Salazopyrin).

Sign in / Sign up

Export Citation Format

Share Document